Afya Ltd. logo

Afya Ltd. (AFYA)

Market Closed
17 Jul, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
13. 90
-0.26
-1.8362%
$
1.27B Market Cap
28.11 P/E Ratio
2.63% Div Yield
48,300 Volume
1.29 Eps
$ 14.16
Previous Close
Add Transaction
Day Range
13.78 14.19
Year Range
13 16.5
Want to track AFYA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
AFYA or LOPE: Which Is the Better Value Stock Right Now?

AFYA or LOPE: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Schools sector might want to consider either Afya (AFYA) or Grand Canyon Education (LOPE). But which of these two stocks is more attractive to value investors?

Zacks | 1 year ago
Should Value Investors Buy Afya (AFYA) Stock?

Should Value Investors Buy Afya (AFYA) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks | 1 year ago
Best Growth Stocks to Buy for July 8th

Best Growth Stocks to Buy for July 8th

STRT, PAHC and AFYA made it to the Zacks Rank #1 (Strong Buy) growth stocks list on July 8, 2025.

Zacks | 1 year ago
Is Afya (AFYA) Stock Outpacing Its Consumer Discretionary Peers This Year?

Is Afya (AFYA) Stock Outpacing Its Consumer Discretionary Peers This Year?

Here is how Afya (AFYA) and American Public Education (APEI) have performed compared to their sector so far this year.

Zacks | 1 year ago
Are Investors Undervaluing Afya (AFYA) Right Now?

Are Investors Undervaluing Afya (AFYA) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks | 1 year ago
New Strong Buy Stocks for June 23rd

New Strong Buy Stocks for June 23rd

DPMLF, EGO, AFYA, ALSN and HMN have been added to the Zacks Rank #1 (Strong Buy) List on June 23, 2025.

Zacks | 1 year ago
Afya Limited Continues To Grow, But Limits Are Also Evident

Afya Limited Continues To Grow, But Limits Are Also Evident

Afya Limited delivered solid Q1 results with 16% YoY revenue growth, driven by acquisitions and organic expansion, and reported strong seasonal margins. Valuation at 11–13x earnings appears fair but not compelling, given long-term risks of market saturation and increased competition in Brazil's medical education sector. Long-term concerns persist as Brazil rapidly increases its doctor supply, potentially pressuring AFYA's enrollment and pricing power in the future.

Seekingalpha | 1 year ago
Afya Limited (AFYA) Q1 2025 Earnings Call Transcript

Afya Limited (AFYA) Q1 2025 Earnings Call Transcript

Afya Limited (NASDAQ:AFYA ) Q1 2025 Earnings Conference Call May 8, 2025 5:00 PM ET Company Participants Virgilio Gibbon - Chief Executive Officer Luis Andre Blanco - Chief Financial Officer Conference Call Participants Flavio Yoshida - Bank of America Lucca Marquezini - Itau Mauricio Cepeda - Morgan Stanley Marcelo Santos - JPMorgan Unidentified Company Representative Thank you for joining us for Afya's conference call. I'm here today with Afya's CEO, Virgilio Gibbon; and our CFO, Luis Andre Blanco.

Seekingalpha | 1 year ago
Afya (AFYA) Surpasses Q4 Earnings and Revenue Estimates

Afya (AFYA) Surpasses Q4 Earnings and Revenue Estimates

Afya (AFYA) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to earnings of $0.36 per share a year ago.

Zacks | 1 year ago
Afya to Expand Medical Education Reach With FUNIC Acquisition

Afya to Expand Medical Education Reach With FUNIC Acquisition

AFYA has announced a share purchase agreement to acquire 100% of FUNIC.

Zacks | 1 year ago
Afya Continues To Be An Opportunity Even After Brazil's Depreciation

Afya Continues To Be An Opportunity Even After Brazil's Depreciation

Afya's 3Q24 results showed 12% organic revenue growth and 16% overall growth, driven by the Unidom acquisition and strong performance in medical education and software segments. The company leveraged its cost structure, achieving a 300bps increase in adj EBITDA margin and a 68% YoY net income growth despite higher financial costs. Afya's valuation remains attractive, with a P/E of 11x and a potential yield of 20% in a few years, justifying a Buy rating.

Seekingalpha | 1 year ago
Afya (AFYA) Q3 Earnings Miss Estimates

Afya (AFYA) Q3 Earnings Miss Estimates

Afya (AFYA) came out with quarterly earnings of $0.32 per share, missing the Zacks Consensus Estimate of $0.36 per share. This compares to earnings of $0.28 per share a year ago.

Zacks | 1 year ago
Loading...
Load More